Empowered Funds LLC Invests $1.63 Million in LivaNova PLC (NASDAQ:LIVN) Stock
Empowered Funds LLC bought a new position in shares of LivaNova PLC (NASDAQ:LIVN) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 13,242 shares of the company’s stock, valued at approximately $1,627,000.
Several other large investors have also recently modified their holdings of the company. grace capital bought a new stake in LivaNova during the second quarter worth $100,000. Cerebellum GP LLC bought a new stake in LivaNova during the third quarter worth $191,000. Envestnet Asset Management Inc. grew its holdings in LivaNova by 1,054.2% during the second quarter. Envestnet Asset Management Inc. now owns 1,662 shares of the company’s stock worth $166,000 after buying an additional 1,518 shares in the last quarter. Cibc Bank USA bought a new stake in LivaNova during the third quarter worth $227,000. Finally, Cubist Systematic Strategies LLC bought a new stake in LivaNova during the first quarter worth $174,000. 87.38% of the stock is currently owned by institutional investors.
NASDAQ:LIVN traded down $3.03 during trading on Friday, reaching $118.81. The company’s stock had a trading volume of 371,799 shares, compared to its average volume of 501,781. The company has a market capitalization of $5.97 billion, a PE ratio of 35.89, a price-to-earnings-growth ratio of 3.68 and a beta of 0.94. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.65 and a quick ratio of 1.21. LivaNova PLC has a 12 month low of $76.14 and a 12 month high of $131.54.
Several brokerages recently issued reports on LIVN. Needham & Company LLC reiterated a “buy” rating and set a $128.00 price target on shares of LivaNova in a report on Wednesday, July 18th. BidaskClub upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a report on Thursday. BTIG Research reiterated a “hold” rating on shares of LivaNova in a report on Thursday, November 1st. Stifel Nicolaus upped their price objective on LivaNova from $135.00 to $140.00 and gave the company a “buy” rating in a research note on Monday, September 17th. Finally, Jefferies Financial Group upped their price objective on LivaNova to $150.00 and gave the company a “buy” rating in a research note on Tuesday, October 2nd. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $126.50.
In other news, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $121.58, for a total transaction of $121,580.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David S. Wise sold 1,500 shares of the stock in a transaction on Monday, October 15th. The stock was sold at an average price of $112.83, for a total value of $169,245.00. The disclosure for this sale can be found here. Insiders sold a total of 9,058 shares of company stock valued at $1,078,683 in the last 90 days. Corporate insiders own 0.41% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally posted by Marea Informative and is the sole property of of Marea Informative. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.mareainformativa.com/2018/11/10/empowered-funds-llc-buys-new-position-in-livanova-plc-livn-updated-updated-updated.html.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Featured Story: Stop Order
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.